SPOTLIGHT: Biocon denies buyout report

Biocon caused a stir this morning after an Indian financial newspaper claimed the country's biggest biotech was nearing a $400 million buyout deal with a U.S. company. But Biocon executives moved quickly to squelch the story, saying the report was "speculative" and inaccurate. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.